Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Portugal

European Research Council grant · Running

ReMAP-PD A Novel 3Rs Microphysiological Alternative Platform for Parkinson’s Disease

Coordinator
Universidade Nova De Lisboa, Portugal
Runs
1 June 2026 to 30 November 2027
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101292750

What the project is doing

In the project's own words, from its summary on CORDIS.

Parkinson's disease (PD), a highly incapacitating neurodegenerative condition of complex and multifactorial origins, remains incurable. As PD cases have skyrocketed by circa 160% since 1990, the burden on society grows heavier. The lack of reliable systems to test new therapeutics, allied with the limitations of current animal gold standard models, have eluded the development of safe and efficacious molecules to fight PD.ReMAP-PD aims at validating a novel 3Rs Microphysiological Alternative Platform for testing new therapeutics against Parkinson’s Disease based on a New Approach Methodology (NAM): a next-generation, human-based cellular disease model - fully aligning with the 3Rs principle of replacing, reducing and refining animal testing.

Building on a novel microphysiological system, this PoC will deliver a scientifically robust and ethically compliant brain-on-chip platform that emulates key pathological features of PD. By validating this new platform for major in vivo PD cellular and molecular hallmarks, ReMAP-PD presents advantages over other NAMs for PD in terms of: ethical constrains related to cell source and accessibility; reagent costs; technical skills and standardization and user friendliness.

With no current robust alternative to test new compounds against PD, ReMAP-PD will not only enhance NAMs translational value but also support a paradigm-shift in disease modelling, accelerating innovation while reducing reliance on animal experimentation. To unlock ReMAP-PD's innovation potential, we plan to conduct performance metric analysis using a well-characterized panel of drug compounds. Positive outcomes will support EU regulatory submission and attract stakeholder interest, while paving the way for ReMAP-PD IPR protection.

Who is involved

OrganisationCityCountryRole
Universidade Nova De LisboaLisboaPortugalCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI